- Home
- BABA vs ABBV Comparison
BABA vs ABBV Comparison
Compare BABA & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BABA | ABBV |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.5B | 400.9B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | BABA | ABBV |
|---|---|---|
| Price | $150.85 | $220.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | $188.69 | ★ $239.16 |
| AVG Volume (30 Days) | ★ 9.4M | 5.8M |
| Earning Date | 02-19-2026 | 02-04-2026 |
| Dividend Yield | 0.70% | ★ 3.14% |
| EPS Growth | ★ 51.05 | N/A |
| EPS | ★ 7.35 | 1.32 |
| Revenue | ★ $142,158,529,239.00 | $59,644,000,000.00 |
| Revenue This Year | $6.30 | $10.38 |
| Revenue Next Year | $11.23 | $9.52 |
| P/E Ratio | ★ $20.55 | $166.65 |
| Revenue Growth | 5.21 | ★ 7.40 |
| 52 Week Low | $80.06 | $164.39 |
| 52 Week High | $192.67 | $244.81 |
Technical Indicators
Market Signals| Indicator | BABA | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 42.94 |
| Support Level | $145.27 | $217.86 |
| Resistance Level | $155.29 | $237.04 |
| Average True Range (ATR) | 3.21 | 5.05 |
| MACD | 0.58 | -0.58 |
| Stochastic Oscillator | 49.03 | 12.51 |
Price Performance
Historical ComparisonAbout BABA Alibaba Group Holding Limited
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.